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Abstract 48"
Objectives 49"
Primary familial brain calcification (PFBC) is a rare neurological disease often inherited as a 50"
dominant trait. Mutations in four genes (SLC20A2, PDGFB, PDGFRB, and XPR1) have been 51"
reported in PFBC patients. Of these, point mutations or small deletions in SLC20A2 are most 52"
common. Thus far, only one large deletion covering entire SLC20A2 and several smaller, 53"
exonic deletions of SLC20A2 have been reported. The aim of this study was to identify the 54"
causative gene defect in a Finnish PFBC family with three affected patients. 55"
Materials and methods 56"
A Finnish family with three PFBC patients and five unaffected subjects was studied. Sanger 57"
sequencing was used to exclude mutations in the coding and splice site regions of SLC20A2, 58"
PDGFRB and PDGFB. Whole-exome (WES) and whole-genome sequencing (WGS) were 59"
performed to identify the causative mutation. A SNP array was used in segregation analysis. 60"
Results 61"
Copy number analysis of the WGS data revealed a heterozygous deletion of ~578 kb on 62"
chromosome 8. The deletion removes the 5’ UTR region, the noncoding exon 1 and the 63"
putative promoter region of SLC20A2 as well as the coding regions of six other genes.  64"
Conclusions 65"
Our results support haploinsufficiency of SLC20A2 as a pathogenetic mechanism in PFBC. 66"
Analysis of copy number variations (CNVs) is emerging as a crucial step in the molecular 67"
genetic diagnostics of PFBC, and it should not be limited to coding regions, as causative 68"
variants may reside in the noncoding parts of known disease-associated genes.  69"
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Introduction 76"
Primary familial brain calcification (PFBC, also previously known as idiopathic basal ganglia 77"
calcification, IBGC, or Fahr’s disease) is a rare neurological disorder with a variable 78"
phenotype. The disease onset is usually between 30 and 50 years and the typical symptoms 79"
include both movement disorders (parkinsonism, dystonia, ataxia, chorea) and 80"
neuropsychiatric disturbances such as psychosis, dementia and frontal or subcortical 81"
cognitive dysfunction. The typical findings, bilateral and symmetric hydroxyapatite deposits, 82"
are seen in basal ganglia, dentate nuclei and thalamus in patients with normal serum levels of 83"
calcium, phosphate, alkaline phosphatase, and parathyroid hormone. However, variation in 84"
the clinical manifestations is common even within families, and asymptomatic individuals 85"
with calcifications have been reported (1-3). 86"
PFBC is often inherited as a dominant trait. The first causative gene, SLC20A2, was reported 87"
in 2012 by Wang et al. (2) Since the original report, many other studies have confirmed that 88"
mutations in this gene account for up to 40 to 50 % of PFBC (4, 5). The other causative genes 89"
are PDGFRB on 5q32 (6), PDGFB on 22q13.1 (7) and XPR1 on 1q25.1 (8). 90"
SLC20A2 codes for an inorganic phosphate (Pi) transporter, PiT-2 that also functions as a 91"
retroviral receptor (9-11). Mutations in SLC20A2 result in impaired phosphate transport and 92"
accumulation of phosphate in the extracellular matrix in the affected brain regions (2, 12). 93"
Functional studies suggest that the deleterious consequences of SLC20A2 mutations are due 94"
to haploinsufficiency rather than dominant-negative effects (2). Studies on Slc20a2 knock-out 95"
mice have shown that PiT-2 also has an important role in maintaining the normal low level of 96"
Pi in the cerebrospinal fluid (CSF) (13). Jensen et al. hypothesized that increased CSF Pi 97"
concentration due to defective PiT-2 could lead to pericyte transformation to a mineralizing 98"
5"
"
cell type and thus calcification of blood vessels (13). Another disease mechanism is proposed 99"
by the functions of PDGFRB and PDGFB which code for the platelet-derived growth factor 100"
receptor β and its ligand, platelet-derived growth factor β, respectively. Mutations in both 101"
Pdgfb and Pdgfrb have been linked to pericyte decifiency and impaired blood-brain barrier 102"
(BBB) integrity in mouse models (14, 15), which might lead to accumulation of calcium 103"
deposits in the brain (6, 7). The protein coded by XPR1 is a retroviral receptor that has been 104"
shown to mediate phosphate export (16). Mutations in XPR1 inhibit phosphate export and are 105"
likely to result in increased concentrations of intracellular phosphate (8). This might lead to 106"
decreased PiT-2-driven Pi uptake from the CSF, resulting in elevated CSF Pi concentration, 107"
as hypothesized by Jensen et al. (13). 108"
Pathogenic SLC20A2 mutations are typically missense (4, 5, 17-24) and nonsense mutations 109"
(4, 17, 25, 26), small deletions (2, 4, 5, 17, 19-21, 27-30) or splice site mutations (4, 5, 19). 110"
Two studies have broadened the mutational spectrum of SLC20A2: In 2014, a large deletion 111"
encompassing the entire coding region of SLC20A2 was reported (25). In a recent study by 112"
David and coworkers, smaller deletions covering exon 2, exon 4 and exons 4 and 5 of 113"
SLC20A2 were found in four patients in a cohort of 24 PFBC patients (31). Thus, analysis of 114"
copy number variations (CNVs) is emerging as a crucial step in molecular genetic diagnostics 115"
of PFBC. 116"
Here we report a novel heterozygous deletion covering the 5’ UTR and most likely the 117"
promoter region of SLC20A2 and extending up to FNTA. The mutation segregates with PFBC 118"
in a Finnish family with three affected subjects. To our knowledge, this is the first report of a 119"
Finnish family with PFBC and the first SLC20A2 mutation in the noncoding region. 120"
 121"
 122"
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Materials and methods 123"
Subjects 124"
We studied a PFBC family with three affected patients, the proband (II:2), his sister (II:5) and 125"
daughter (III:1). The inheritance pattern was consistent with autosomal dominant disease. 126"
The pedigree of the family is shown in Figure 1b. All patients were clinically examined at the 127"
Lapland central hospital. Two affected patients and five unaffected persons from the family 128"
were recruited for the study. No DNA from the deceased patient (II:2) was available for 129"
genetic testing. The study was approved by the Ethics Committee of Oulu University 130"
Hospital. Informed consent was obtained from all individual participants included in the 131"
study. 132"
 133"
The proband, II:2, presented with symmetrical blepharospasm and bilateral facial spasm at 134"
the age of 66 years. Botulinumtoxin A injection treatment had only minor effect on the 135"
spasms.  No additional findings were noted in clinical neurological examination. Brain 136"
magnetic resonance imaging (MRI) and computed tomography (CT) studies showed bilateral 137"
calcifications in basal ganglia and cerebellum (Figure 1a). Lowered perfusion in these brain 138"
areas was also noted in single positron emission tomography (SPECT) examination.  The 139"
patient died of prostate cancer at the age of 69 years. 140"
 141"
Patient II:5 had motor deficits, balance problems and memory disturbance. Clinical 142"
neurological examination was performed at 70 years. The patient had slight apraxia, mild 143"
balance impairment and lower limb ataxia but no dystonic movements. Mini Mental State 144"
Examination (MMSE) score was 19/30 consistent with mild dementia.  Brain CT showed 145"
7"
"
calcifications in corona radiata and in cerebellum, anterior to lateral ventricles and vascular 146"
degeneration. No hippocampal atrophy was seen. 147"
 148"
The third affected patient, III:1, was diagnosed with torticollis spasmodica at the age of 29 149"
years. She responded well to botulinumtoxin A injection treatment. Brain MRI showed 150"
bilateral calcifications in the basal ganglia, thalamus and nucleus dentatus. 151"
 152"
Serum levels of calcium, phosphate, alkaline phosphatase and parathyroid hormone were 153"
normal in all three patients. 154"
 155"
Genetic methods 156"
DNA was extracted from peripheral EDTA blood with the Illustra Nucleon BACC3 Genomic 157"
DNA Extraction Kit (GEHealthcare, Little Chalfont, Buckinghamshire, UK). The coding 158"
regions and flanking intronic splice sites of SLC20A2 (NM_006749.4), PDGFRB 159"
(NM_002609.3) and PDGFB (NM_002608.3) were amplified by PCR and sequenced in both 160"
directions using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 161"
CA, USA).  162"
Whole exome sequencing (WES) of the two affected patients and one unaffected subject was 163"
performed by the Institute for Molecular Medicine Finland (FIMM, University of Helsinki, 164"
Finland). Exome enrichement was done using the SeqCap EZ Human Exome Library v3.0 165"
(Roche Nimblegen, Basel, Switzerland) and the resulting libraries were sequenced on the 166"
Illumina HiSEQ platform (Illumina, San Diego, CA, USA) to a mean target coverage of 167"
58.8x (II:5), 62.4x (III:1), and 31.3x (III:2). Sequences were aligned to GRCh37/hg19, 168"
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variants called using the variant calling pipeline (vcp) developed at FIMM and the resulting 169"
variants were annotated with ANNOVAR(32).  170"
Whole genome sequencing (WGS) of one affected and one unaffected subject was done by 171"
NGI Sweden (The National Genomics Infrastructure, Science for Life Laboratory, Solna, 172"
Sweden). Libraries were prepared using the TruSeq DNA PCR-free kit and sequenced on a 173"
HiSeq X Platform (Illumina, San Diego, CA, USA) to a mean coverage of 41.78x (III:1) and 174"
41.75x (III:2). Sequences were aligned to GRCh37/hg19. Variant calling pipeline followed 175"
the GATK best practice guidelines. Small indels and SNVs were annotated with SnpEff(33) 176"
and ANNOVAR. Structural variants and larger copy number variants were identified by 177"
cn.mops(34) and Manta (https://github.com/Illumina/manta). 178"
Additionally, five samples (II:3, II:4, II:5, II:6, II:7) were genotyped using genome-wide SNP  179"
array, the HumanOmniExpress Bead chip (Illumina, San Diego, USA). 180"
Results  181"
Sanger sequencing ruled out coding and splice site mutations in SLC20A2, PDGFRB and 182"
PDGFB. Exome sequencing did not result in any potentially causative variants shared by the 183"
two affected patients. Copy number analysis of the WGS data (subject III:1) revealed a 184"
heterozygous deletion of 578,164 bp on chromosome 8 (genomic coordinates chr8: 185"
42,338,721 - 42,916,885) (Supporting table 1, Supporting figure 1). The deletion was also 186"
visible in the SNP array data (subject II:5) with breakpoints at rs11780448 (chr 8: 187"
42,325,328) and rs13248091 (chr8: 42,929,226 bp) (Supporting figure 2). The unaffected 188"
subject III:2 did not have the deletion based on WGS (Supporting table 1, Supporting figure 189"
1).  190"
9"
"
The deletion removes the noncoding exon 1, 5’ UTR region and the putative promoter region 191"
of SLC20A2 as well as the whole coding regions of six other genes (SMIM19, CHRNB3, 192"
CHRNA6, THAP1, RNF170, and HOOK3). The other deletion breakpoint is located between 193"
second and third exon of FNTA. 194"
In order to test whether the deletion segregates with PFBC in this family, we genotyped 195"
additional four unaffected family members on a SNP array. The combination of  WGS and 196"
SNP array data  showed complete segregation of the deletion with the disease: the deletion 197"
was found in the two affected family members from whom DNA was available for testing, 198"
and was absent in the five unaffected relatives (Figure 1b, Supporting figure 2). 199"
Discussion 200"
Large deletions in causative genes for PFBC have been described in a few families. The first 201"
causative large copy number variant (CNV) for PFBC was reported by Baker el al. in a 202"
Canadian family (25). A partial deletion of PDGFB was subsequently described by Nicolas et 203"
al. (35). Recently, smaller exonic deletions of SLC20A2 were reported in four patients (31). 204"
We identified a ~578 kb deletion in a Finnish family with PFBC using both WGS and a SNP 205"
array. The exact breakpoints of the deletion could be identified from the whole genome 206"
sequencing data. 207"
The deletion abolishes the first noncoding exon, the 5’ UTR region and most likely the 208"
promoter region of SLC20A2 leaving the entire coding region intact. The coding regions of 209"
six other genes (SMIM19, CHRNB3, CHRNA6, THAP1, RNF170, and HOOK3) are deleted. 210"
At the centromeric breakpoint, the putative promoter region and first two exons of FNTA are 211"
deleted but the remaining exons are present in two copies (Figure 1c). 212"
10"
"
The deletion reported by Baker et al. covers the entire coding region of SLC20A2 and most 213"
likely results in reduced expression (25). The exonic deletions reported by David et al. 214"
presumably lead to loss of function by removing the translation initiation codon (exon 2 215"
deletion), causing a frameshift (exon 4 deletion) or removing two transmembrane domains 216"
(deletion of exons 4 and 5) (31) . The deletion reported here starts between the first two exons 217"
of SLC20A2 removing the noncoding exon 1, 5’ UTR and the putative promoter region 218"
upstream of the transcription start site. Generally no transcript is produced if the promoter 219"
region is missing. We propose that the deletion leads to reduced expression of SLC20A2 and 220"
is thus causative of PFBC in the Finnish family. 221"
Baker et al. reported dystonia in 8 of 11 affected individuals of the family with SLC20A2 222"
deletion (25). They hypothesized that deletion of THAP1 might contribute to this as 223"
mutations in THAP1 have been linked to idiopathic torsion dystonia of mixed type (DYT6, 224"
OMIM 602629). Interestingly, the youngest patient described here also had cervical dystonia 225"
(torticollis spasmodica). The possible phenotypic consequences of the other deleted genes are 226"
currently unclear. Genes affected by the deletion code for small integral membrane protein 227"
(SMIM19), beta and alpha subunits of the neuronal cholinergic nicotinic receptor (CHRNB3 228"
and CHRNA1), endoplasmic reticulum membrane ubiquitin ligase (RNF170), cytosolic 229"
coiled-coil microtubule binding protein (HOOK3), and farnesyltransferase (FNTA). Apart 230"
from RNF170, most of them have not been linked to neurological diseases. A missense 231"
mutation (p.Arg199Cys) in RNF170  has been shown to segregate with autosomal dominant 232"
sensory ataxia in two families (36) but, as also noted by Baker et al.(25), the suggested 233"
disease-mechanism was gain-of-function. Thus, the possible effects of deletion of one 234"
RNF170 allele are still unknown.  235"
Conclusions 236"
11"
"
Our results give further support for haploinsufficiency of SLC20A2 as a pathogenetic route in 237"
PFBC and suggest that deletion of regulatory regions of SLC20A2 is sufficient to cause the 238"
disease. The partial deletion of SLC20A2 described here demonstrates that copy number 239"
analysis is essential when screening for mutations in known causative genes in primary 240"
familial brain calcification. Ideally, CNV analysis should not be limited to coding regions as 241"
causative copy number variations may reside in regulatory regions of known disease-242"
associated genes. 243"
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Titles and legends to figures 355"
Figure 1. (a) Brain CT of patient II:2 showing calcification (marked with arrows) in basal 356"
ganglia and cerebellum. (b) Pedigree of the family with screenshots of SNP array data and 357"
the deletion breakpoint in SLC20A2 in WGS data visualized using the Integrative Genomics 358"
Viewer (IGV) (37, 38). Circles mark females, squares males. Affected persons are marked by 359"
a filled symbol and deceased persons with a slashed symbol. DNA samples were available 360"
from persons marked with an asterisk. (c) Schematic drawing of the deletion area on 8p11.2. 361"
The deletion reported by Baker et al. (25) is shown for comparison. Orientations of the genes 362"
are marked with arrows.   363"
"364"

Supplementary,table,1.,WGS,analysis,results,showing,the,presence,of,heterozygous,deletion,affecting,SLC20A2,in,PFBC,patient's,sample,(greyFshaded,columns).,
! ! ! ! ! ! ! ! !1a.,,cn.mops,analysis,results,from,the,deletion,area,(CN2,indicates,two,copies,and,CN1,one,copy,of,a,genomic,segment).,
! ! ! ! ! ! ! ! !CHROM, START, END, WIDTH, Reference_sample,1, Reference,sample_2, PFBC_sample, PFBC_control, GENE,
8! 42339001! 42429000! 90000! CN2! CN2! CN1! CN2! SLC20A2;SMIM19!
8! 42431001! 42543000! 112000! CN2! CN2! CN1! CN2! !!
8! 42546001! 42799000! 253000! CN2! CN2! CN1! CN2! CHRNB3;CHRNA6;THAP1;RNF170;MIR4469;HOOK3!
8! 42800001! 42813000! 13000! CN2! CN2! CN1! CN2! HOOK3!
8! 42816001! 42843000! 27000! CN2! CN2! CN1! CN2! HOOK3!
8! 42844001! 42877000! 33000! CN2! CN2! CN1! CN2! HOOK3!
8! 42878001! 42917000! 39000! CN2! CN2! CN1! CN2! HOOK3;FNTA!
!
1b.,,Manta,analysis,results,from,the,deletion,area,,(0/1,indicates,heterozygous,deletion,,0/0,indicates,wild,type).,
!
! ! ! ! ! ! ! ! ! ! !CHROM, POS, ID, REF, ALT, FILTER, INFO, PFBC_sample, PFBC_control, Reference_sample1, Reference_sample2,
8! 42338721! MantaDEL:159946! A! <DEL>! PASS! END=42916885! 0/1:PASS! 0/0:PASS! 0/0:PASS! 0/0:PASS!
!


